Production (Stage)
Ginkgo Bioworks Holdings, Inc.
DNA
$7.42
$0.639.28%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.34% | 26.16% | 60.65% | -30.24% | -52.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.34% | 26.16% | 60.65% | -30.24% | -52.98% |
| Cost of Revenue | 30.92% | 45.55% | 73.38% | -24.18% | -58.87% |
| Gross Profit | 26.20% | 21.61% | 58.83% | -31.99% | -50.72% |
| SG&A Expenses | -30.22% | -20.12% | -36.25% | -31.46% | -36.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 312.85% | -- | -- | 123.76% | -- |
| Total Operating Expenses | -36.29% | -26.89% | -42.47% | -15.57% | -27.83% |
| Operating Income | 50.01% | 38.86% | 72.52% | 8.56% | 18.43% |
| Income Before Tax | 45.22% | 49.10% | 81.26% | -25.25% | 19.04% |
| Income Tax Expenses | 183.87% | -64.14% | -1,604.55% | 183.58% | -62.20% |
| Earnings from Continuing Operations | 45.18% | 49.20% | 81.38% | -25.31% | 19.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.18% | 49.20% | 81.38% | -25.31% | 19.06% |
| EBIT | 50.01% | 38.86% | 72.52% | 8.56% | 18.43% |
| EBITDA | 55.48% | 44.39% | 79.25% | 9.35% | 17.11% |
| EPS Basic | 49.35% | 53.33% | 82.62% | -17.91% | 22.67% |
| Normalized Basic EPS | 53.68% | 41.68% | 78.14% | 16.67% | 21.40% |
| EPS Diluted | 49.38% | 53.37% | 82.61% | -17.53% | 22.65% |
| Normalized Diluted EPS | 53.66% | 41.64% | 78.14% | 16.68% | 21.36% |
| Average Basic Shares Outstanding | 8.24% | 8.84% | 7.12% | 6.28% | 4.67% |
| Average Diluted Shares Outstanding | 8.19% | 8.78% | 7.13% | 6.29% | 4.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |